The Latest Breaking News from BioCryst

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted  Priority Review designation and assigned a target actin date of February 17,…

Tucked in its Q1 earnings release, a voluntary pause for BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) complement-mediated disease therapy has been upgraded to a partial FDA clinical hold. The update clarified why the company paused trials testing ​​BCX9930 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder marked by the destruction of red blood cells…

Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down 1.62% over the last 24 hours, at $10.94 per share.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation.  Patients currently enrolled in the trials are continuing on the study…